Author:
Kirkpatrick D. Lynn,Millard Jeffrey
Abstract
AbstractIn the current COVID-19 pandemic context, Ensysce and its subsidiary Covistat have been working to repurpose nafamostat mesylate as an effective oral and inhalation treatment against SARS-CoV-2 infection. Prior reports used cell lines to demonstrate the antiviral potential of nafamostat against coronaviral infections and determined its mechanism of action through inhibition of transmembrane protease serine 2 (TMPRSS2). We selected a biologically relevant pre-clinical experimental model of SARS-CoV-2 lung infection using a 3D human reconstituted airway epithelial model of nasal origin to characterize the effects of nafamostat on tissue-level cellular ultrastructure and viral infection kinetics. Our results confirm the not only the relevance of this model for the preclinical evaluation of safety and efficacy of antiviral candidates, but also the highly potent nature of nafamostat SARS-CoV-2 antiviral activity. The studies described herein provided evidence demonstrating the therapeutic potential of nafamostat against COVID-19, as well as its safety upon exposure to lung airway cellular.One Sentence SummaryUsing a human airway model, study demonstrates the powerful inhibitory effect of nafamostat on SARS-CoV-2 genome copy detection when applied apically.
Publisher
Cold Spring Harbor Laboratory
Reference9 articles.
1. Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis
2. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int;Archs Allergy Appl Immun,1982
3. Hoffmann M , Kleine-Weber H , Schroeder S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4.
4. Establishment of a Human 3D Tissue-Based Assay for Upper Respiratory Tract Absorption;Applied In Vitro Toxicology,2018
5. Honda H , Nakano S , Kunishima C et al. Post-marketing surveillance (2003-2007) report of FUTHAN 10,50 Injection (English Translation). Safety Information Management Department, Torii Pharmaceutical Co., Ltd., Tokyo, Japan.